 Verve Therapeutics announced disappointing lab results for its CRISPR gene-editing approach to high cholesterol, and VERV stock skidded. The post Why Shares Of CRISPR-Focused Verve Therapeutics Just Took A Grim Turn appeared first on Investors Business Daily. 